Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
4D Molecular Therapeutics, Inc. (FDMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Mehra Uneek (See Remarks) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 229,634 options to buy @ $12.73, valued at $2.9M
09/26/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
08/16/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration • Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July, nearly two quarters ahead of initially projected enrollment completion • Presented positive interim data from aerosolized 4D-710 Phase 1/2 AEROW clinical trial for patients with cystic fibrosis lung disease • Anticipate multiple clinical data and regulatory interaction updates onlead clinical-stage product candidates 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease over the next 12 mo..."
06/12/2023 4 Bizily Scott (Chief Legal and HR Officer) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Sold 3,750 shares @ $20.85, valued at $78.2k
Exercised 3,750 options to buy @ $8.04, valued at $30.2k
06/06/2023 4 Bizily Scott (Chief Legal and HR Officer) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Sold 2,247 shares @ $18.3103, valued at $41.1k
Exercised 1,875 options to buy @ $6.49, valued at $12.2k
05/25/2023 4 MILLIGAN JOHN F (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 33,750 options to buy @ $17.98, valued at $606.8k
05/25/2023 4 Tomasello Shawn (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 22,500 options to buy @ $17.98, valued at $404.6k
05/25/2023 4 Miller-Rich Nancy (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 22,500 options to buy @ $17.98, valued at $404.6k
05/25/2023 4 THEUER CHARLES (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 22,500 options to buy @ $17.98, valued at $404.6k
05/25/2023 4 GRAY SUSANNAH (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 22,500 options to buy @ $17.98, valued at $404.6k
05/25/2023 4 Chacko Jacob (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 22,500 options to buy @ $17.98, valued at $404.6k
05/25/2023 4 Kasahara Noriyuki (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Granted 22,500 options to buy @ $17.98, valued at $404.6k
05/25/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/16/2023 4 Moretti August J (CFO) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Exercised 3,000 options to buy @ $9.41, valued at $28.2k
05/11/2023 4 VIKING GLOBAL INVESTORS LP (10% Owner) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Bought 850,000 shares @ $16, valued at $13.6M
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual Meeting • On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023 • Acquired all worldwide rights to short-form human complement factor H from Aevitas Therapeutics, Inc. and announced sCFH as payload for 4D-175 lead product candidate for geographic atrophy • Multiple additional clinical data updates on clinical-stage product candidates expected later in 2023, including on 4D-710 for cystic fibrosis lung disease in Q2 2023 • Closed upsized public offer..."
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Evercore Group, L.L.C",
"Opinion of Latham & Watkins LLP"
05/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/04/2023 4 Kirn David (CEO) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Gifted 600,000 shares @ $0
Gifted 600,000 shares @ $0
05/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/03/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 144 Form 144 - Report of proposed sale of securities:
04/21/2023 144 Form 144 - Report of proposed sale of securities:
04/05/2023 3 Kim Robert Young (Chief Medical Officer) has filed a Form 3 on 4D Molecular Therapeutics, Inc.
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration and diabetic macular edema , 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy • Demonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platform • Expanded preclinical pipeline with large market geographic atrophy and alpha-1 antitrypsin deficiency lung disease programs • On track for multiple clinical data updates on lead clinical-stage product candidates during 2023 • Cash, cash equivalents and marketable ..."
03/15/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 4 Kirn David (CEO) has filed a Form 4 on 4D Molecular Therapeutics, Inc.
Txns: Sold 17,090 shares @ $20.9314, valued at $357.7k
Sold 907 shares @ $21.4897, valued at $19.5k
Sold 16,449 shares @ $20.224, valued at $332.7k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy